On June 11, 2025, Genprex, Inc. announced a $12.5 million commitment from Lincoln Park Capital Fund for purchasing its common stock, expected to support general corporate purposes. The company also updated on its clinical trials involving its oncology gene therapy programs, including patient enrollment and FDA designations for treatments.